Premarket Movers Oct 20, 2026: Why BRZE, FRTT, AIXI Are Up

BRZE — Braze, Inc. (+51.2%)

Braze is trading at $45.45 in premarket, up 51.2% from the prior close. About 2.3 million shares have changed hands so far, already above its 20-day average of roughly 1.96 million. Premarket volume is lighter than regular hours, so that is a heavy early read.

The likely driver is an acquisition report. Headlines this morning say Salesforce signed a definitive agreement to buy Braze for about $5.7 billion (Yahoo Finance, Investing.com). A takeover bid typically pushes a stock toward the deal price. One caution: some price quotes seen this morning showed the stock near $30, a far smaller gain, so the size of the premarket move is not confirmed across sources. Check the deal terms in the official announcement or an SEC filing before relying on it.

Into this move, the prior-day setup was constructive but unremarkable. The daily chart showed a bullish moving-average stack, RSI of 61, ADX of 22 and a price 17.0% below its 52-week high. StockSetups gave it a relative strength rating of 87, a conviction score of 76/100 (grade A) and a trend-template score of 7. It had no active pattern lane.

Short interest is 9.8 million shares, or 3.4 days to cover (the days it would take shorts to buy back at average volume). The squeeze score is 54/100. With a deal in play, shorts are more likely to cover than to squeeze it further.

FRTT — Fort Technology Inc (+43.0%)

Fort Technology is trading at $0.77 premarket, up 43.0%, on 92.2 million shares. Its 20-day average volume is only about 85,000, so this is an enormous surge in activity.

The likely catalyst is a press release this morning (GlobeNewswire, 07:32 ET). Its majority-owned subsidiary, Logia USA, signed an exclusive distributorship with HVAC equipment representative Schwab Vollhaber Lubratt. It covers parts of North Dakota, Minnesota, Wisconsin, Iowa, Michigan's Upper Peninsula and Illinois through July 31, 2027, unless it ends early. Reported gains vary by source and time, from about 19% to 42%, and no source explicitly ties the move to the release beyond timing.

The prior-day chart was weak: RSI 14, a price 84.1% below its 52-week high, a technical rank of 4 and a conviction score of 0/100 (grade D). A low float stock has few shares available to trade, which lets volume swing the price violently. Free float here is 22.1%. Short interest is tiny (50,454 shares, 0.1 days to cover), so this is not a squeeze setup, with a squeeze score of 16/100. A 13D/G filer holds 72.5%.

AIXI — Xiao-I Corp (+27.3%)

Xiao-I is trading at $2.80 premarket, up 27.3%, on about 6.1 million shares versus a 20-day average of 13.6 million. Its market cap is only $2.0M, which makes it extremely small and thinly valued.

No news, filing or announcement explains the move. The latest filing is a routine 6-K from October 1. A Stocktwits headline on October 19 described a 130% surge and a first break above the 50-day moving average in over five months, with retail traders calling it a breakout. That points to a momentum-driven move. It also drew one mention on r/pennystocks.

The prior-day chart showed a bearish belt hold candle, a bearish moving-average stack, RSI of 45 and a price 99.2% below its 52-week high. Its conviction score was 4/100 (grade D). The squeeze score is 52/100 with 98.6% free float, short interest of 296,222 shares and a short-sale restriction (SSR) active, which limits new short selling on stocks that have dropped sharply. Spikes in names like this often reverse quickly.

RAPP — Rapport Therapeutics, Inc. (+21.6%)

Rapport is trading at $34.75 premarket, up 21.6%, on 1.95 million shares, versus a 20-day average of about 427,000. Some outlets (Yahoo Finance, GuruFocus) report gains of more than 50% earlier this morning, so the move is fluid.

The catalyst is positive topline Phase 2 results for RAP-219 in acute bipolar mania, announced today. The randomized, placebo-controlled trial enrolled 253 adults with bipolar I disorder in an acute manic episode. It met its primary and secondary endpoints, with a placebo-adjusted improvement at Week 3 on the YMRS total score of 3.1 points (p=0.045). Wells Fargo rated the stock Overweight with a $51 target, while flagging risks around agitation-related adverse events and a high discontinuation rate.

The prior-day setup was beaten down: RSI 30, a mixed moving-average stack, a bullish harami candle and a price 45.6% below its 52-wk high. Conviction was 22/100 (grade D). Short interest is 2.2 million shares, or 8.2 days to cover, with a squeeze score of 56/100. Shorts caught offside could add fuel. Biotech trial moves can also reverse fast on details.

MYGN — MYRIAD GENETICS INC (+20.4%)

Myriad Genetics is trading at $5.08 premarket, up 20.4%, on about 1.45 million shares, compared with a 20-day average of 1.7 million. Market cap is $403.6M.

The catalyst is a definitive agreement with Labcorp, announced today, for Myriad to sell its prenatal health testing business to Labcorp. Terms are not covered here. The stock had fallen 8.51% to $3.98 on October 16, so part of this move may be a rebound.

The prior-day chart showed no pattern lane, a mixed moving-average stack, RSI 54, ADX 33 and a price 48.4% below its 52-week high. Its conviction score was 18/100 (grade D), with a relative strength rating of 12. Short interest is 7.8 million shares (5.0 days to cover), and the squeeze score is 42/100.

The bottom line

Chasing extended premarket gainers is high-risk. Premarket volume is thin, spreads are wide, and moves often fade once the 9:30 AM ET open brings more liquidity. Patterns and squeezes fail often, so size positions carefully, use stops (see where to place a stop loss) and do your own research. This is educational content, not advice.

StockSetups scans the full US universe after every close and every premarket morning. For more on gaps, see the gap fill strategy guide.